The Medicinal Chemistry Core is a newly proposed CCSG Core. The Medicinal Chemistry Core Laboratory was developed to provide the needed expertise in the area of synthesis of small molecules, modified peptides and bioconjugates for biomedical research by the Cancer Center research community. Creation of this Core was in direct response to a clearly defined need for providing synthesis of chemical reagents needed for preclinical studies (not for clinical drug development). The guiding principle was that the Center was not attempting to establish a GMP chemical production facility, but a chemical synthesis core laboratory to provide reagent grade compounds for use in validation and proof-of-principle target discovery studies. To accomplish this, there are a large number of investigators within the Center who have a need for a Medicinal Chemistry Core to provide unique reagents. These reagents are needed both for the study of the role of specific molecular targets controlling the growth and survival of cancer cells, as well as for the development of related reagents for cancer treatment. From the 2002 inception of the Medicinal Chemistry Core, its mission has been to provide very specific unique reagents to allow proof of principle and general drug discovery studies and accelerate basic sciences studies. The main purpose of the Medicinal Chemistry Core is: (1) To design and synthesize bioactive molecules in the most cost effective manner possible. (2) To optimize methods of purification of bioactive molecules at high yield. (3) To provide NMR, Mass spectrometry, and HPLC analysis for characterization of new anticancer agents. (4) To provide investigators with custom synthesis of anticancer agents in amounts ranging from milligrams to grams. (5) To provide experience and intuition for identification and optimization of lead compounds as well as promising reagents. This application requests support for a resource which continues to fulfill an essential role for peer reviewed research within the SKCCC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Peprah, Sally; Curreiro, Frank C; Hayes, Jennifer H et al. (2018) A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012. Cancer Causes Control 29:445-453
Springer, Simeon U; Chen, Chung-Hsin; Rodriguez Pena, Maria Del Carmen et al. (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7:
Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917
Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218
Dean, Lorraine T; Schmitz, Kathryn H; Frick, Kevin D et al. (2018) Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. J Cancer Surviv 12:306-315
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Leadem, Benjamin R; Kagiampakis, Ioannis; Wilson, Catherine et al. (2018) A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine. Cancer Res 78:1127-1139
Danilova, Ludmila; Anagnostou, Valsamo; Caushi, Justina X et al. (2018) The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res 6:888-899
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597

Showing the most recent 10 out of 2393 publications